ROCHE/PDL ZENAPAX HUMANIZED MAb FOR PREVENTION OF KIDNEY TRANSPLANT REJECTION TO BE LAUNCHED WEEK OF DEC. 15; LONG TERM EFFECTS ON IMMUNE SYSTEM UNDER STUDY
Executive Summary
Roche plans to launch Zenapax (daclizumab) within a week of the humanized IgG1 monoclonal antibody's approval Dec. 10.